Maximising clinical benefit with adequate patient management beyond the second line in mCRC

New therapeutic options for refractory metastatic colorectal cancer (mCRC) include trifluridine/tipiracil (TAS-102) and regorafenib. However, the optimal chemotherapeutic regimen for use of each agent beyond the second line for patients with mCRC remains unclear and various factors may influence tre...

Descripción completa

Detalles Bibliográficos
Autores principales: Argiles, Guillem, Arnold, Dirk, Prager, Gerald, Sobrero, Alberto F, Van Cutsem, Eric
Formato: Online Artículo Texto
Lenguaje:English
Publicado: BMJ Publishing Group 2019
Materias:
Review
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555611/
https://www.ncbi.nlm.nih.gov/pubmed/31231561
http://dx.doi.org/10.1136/esmoopen-2019-000495

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC6555611/
https://www.ncbi.nlm.nih.gov/pubmed/31231561
http://dx.doi.org/10.1136/esmoopen-2019-000495

Ejemplares similares